Sanofi to Aid in Production of Pfizer-BioNTech Vaccine
Sanofi has agreed to bottle and package at least 125 million doses of the COVID-19 vaccine BNT162b2 from Pfizer and BioNTech.
Sanofi, one of the largest drug and vaccine producers in the world, has agreed to bottle and package at least 125 million doses of coronavirus 2019 (COVID-19) vaccine BNT162b2 from Pfizer and BioNTech. The France-based company will use its Frankfurt facilities to aide in late-stage production for the vaccines from their pharmaceutical rivals, for distribution in the European Union, beginning this summer, according to an announcement made Wednesday.
In the meantime, Sanofi remains engaged in the development of its own COVID-19 vaccine, in collaboration with partner GlaxoSmithKline (GSK). The group most recently delayed its vaccine production and real-world assessment after observed failure to produce a strong immune response in older participants of a phase 1/2 trial.
The UK had originally ordered 60 million doses of the Sanofi and GSK vaccine, which investigators reported last month as having a low immune response in participants aged ≥50 years old, likely due to “insufficient concentration of the antigen.” This setback, combined with shortcomings in Pfizer-BioNTech production and delays from the AstraZeneca-University of Oxford vaccine—as well as a highly transmissible SARS-CoV-2 variant first observed in southeast England—has put significant strain on the region’s immunity-building efforts.
